Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  European Journal of Cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0959-8049(96)00292-4PMID 8943660
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo

  2004cited by this paper
• Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

  1997cited by this paper
• Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective.

  1996cited by this paper
• CPT-11: clinical experience in phase I studies.

  1996cited by this paper
• Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.

  1995cited by this paper
• Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.

  1995cited by this paper
• Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.

  1994cited by this paper
• Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.

  1994cited by this paper
• Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.

  1994cited by this paper
• Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

  1994cited by this paper
• Les tumeurs gastro-intestinales

  1993cited by this paper
• Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.

  1993cited by this paper
• Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.

  1993cited by this paper
• Phase I and pharmacokinetic trial of weekly CPT-11.

  1993cited by this paper
• Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

  1993cited by this paper
• Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion.

  1992cited by this paper
• Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer.

  1991cited by this paper
• The Modulation of Fluorouracil With Leucovorin in Metastatic Colorectal Carcinoma A Prospective Randomized Phase III Trial

  1990cited by this paper
• [Phase I clinical study of CPT-11. Research group of CPT-11].

  1990cited by this paper
• The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.

  1989cited by this paper
• Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.

  1989cited by this paper
• DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts.

  1989cited by this paper
• A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.

  1988cited by this paper

• Chemoresistance in Colorectal Malignancies: Molecular Mechanisms and Strategies to Overcome.

  2022cites this paper
• A Concise Overview of Chemotherapeutic Drugs in Gastrointestinal Cancers: Mechanisms of Action and Resistance

  2020cites this paper
• Pharmacologic resistance in colorectal cancer: a review

  2016cites this paper
• Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

  2014cites this paper
• Topoisomerase I Inhibitors: Current Use and Prospects

  2012cites this paper
• A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

  2012cites this paper
• Sequential Administration of 5-Fluorouracil (5FU)/Leucovorin (LV) Followed by Irinotecan (CPT-11) at Relapse versus CPT-11 Followed by 5-FU/LV in Advanced Colorectal Carcinoma

  2007cites this paper
• Cytoreduction and hyoerthermic intraperitoneal chemotherapy in peritoneal carcinomastosis of colorectal origin

  2007cites this paper
• Advances in Brief Interleukin 15 Offers Selective Protection from Irinotecan-induced Intestinal Toxicity in a Preclinical Animal Model 1

  2006influential citation
• Single-Agent Irinotecan for Recurrent/Metastatic Colorectal Cancer: A Retrospective Analysis

  2006cites this paper
• Phase II Trial of Gemcitabine Plus Irinotecan In Patients With Esophageal Cancer: A Southwest Oncology Group (SWOG) Trial

  2006cites this paper
• Effects of irinotecan/5-fluorouracil combination on thymidylate synthase and cell cycle in human colon carcinoma cell line

  2006cites this paper
• FOLFOX versus FOLFIRI: a comparison of regimens in the treatment of colorectal cancer metastases.

  2005cites this paper
• Phase II study of irinotecan (CPT‐11) as salvage therapy for advanced nasopharyngeal carcinoma

  2005cites this paper
• Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: a prospective study.

  2005cites this paper
• Cytoreduction and hyoerthermic intraperitoneal chemotherapy in peritoneal carcinomastosis of colorectal origin

  2004cites this paper
• Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma

  2004cites this paper
• Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).

  2004cites this paper
• Long-Term Survival of Peritoneal Carcinomatosis of Colorectal Origin

  2004cites this paper
• The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.

  2002cites this paper
• Phase I‐II Study of Irinotecan in Combination With Mitomycin C in Patients With Advanced Gastrointestinal Cancer

  2001cites this paper
• Camptothecin schedule and timing of administration with irradiation.

  2001cites this paper
• Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.

  2000cites this paper
• Intensified Regression of Colon Cancer Liver Metastases in Mice Treated with Irinotecan and the Immunomodulator JBT 3002

  2000cites this paper
• Recent developments of rebeccamycin analogues as topoisomerase I inhibitors and antitumor agents.

  2000cites this paper
• Metabolism of Irinotecan ( CPT-11 ) by CYP 3 A 4 and CYP 3 A 5 in Humans 1

  2000cites this paper
• Management of hepatic metastases.

  1999cites this paper
• Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.

  1999cites this paper
• Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.

  1999cites this paper
• Nonoperative Management of Primary Colorectal Cancer in Patients With Stage IV Disease

  1999cites this paper
• Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.

  1999cites this paper
• Topoisomerase I inhibitors in the treatment of colorectal cancer.

  1999cites this paper
• The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells

  1999cites this paper
• Phase I I S tudy o f I rinotecan P lus C isplatin i n P atients With A dvanced N on-Small-Cell L ung C ancer

  1999cites this paper
• [Irinotecan pharmacokinetics].

  1998cites this paper
• The importance of stabilization as an endpoint in the treatment of metastatic colorectal carcinoma: recent quality of life studies

  1998cites this paper
• Camptothecin radiation sensitization: mechanisms, schedules, and timing.

  1998cites this paper
• Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model.

  1998cites this paper
• Improved survival in patients with advanced colorectal carcinoma failing 5-fluorouracil who received irinotecan hydrochloride and have high intratumor C-fos expression.

  1998cites this paper
• Irinotecan: A New Antineoplastic Agent for the Management of Colorectal Cancer

  1998cites this paper
• Clinical Pharmacokinetics of Irinotecan

  1997cites this paper
• Future directions for clinical research with CPT-11 (irinotecan).

  1996cites this paper
• Future directions for clinical research with CPT-11 (irinotecan).

  1996influential citation
• Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation.

  1996cites this paper